| Literature DB >> 34407988 |
Mika Kivimäki1,2,3, Keenan A Walker4,5, Jaana Pentti2,3,6, Solja T Nyberg2, Nina Mars7, Jussi Vahtera6,8, Sakari B Suominen6,9, Tea Lallukka2, Ossi Rahkonen2, Olli Pietiläinen2, Aki Koskinen3, Ari Väänänen3, Jatinderpal K Kalsi10, Marcel Goldberg11,12, Marie Zins11,12, Lars Alfredsson13,14, Peter J M Westerholm15, Anders Knutsson16, Töres Theorell17, Jenni Ervasti3, Tuula Oksanen18, Pyry N Sipilä2, Adam G Tabak10,19, Jane E Ferrie10,20, Stephen A Williams21, Gill Livingston22,23, Rebecca F Gottesman4, Archana Singh-Manoux10,12, Henrik Zetterberg24,25, Joni V Lindbohm10,2.
Abstract
OBJECTIVES: To examine the association between cognitively stimulating work and subsequent risk of dementia and to identify protein pathways for this association.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34407988 PMCID: PMC8372196 DOI: 10.1136/bmj.n1804
Source DB: PubMed Journal: BMJ ISSN: 0959-8138
Fig 1Selection of cohort studies to analyse three associations: cognitive stimulation-dementia (analysis 1), cognitive stimulation-proteins (analysis 2), and proteins-dementia (analysis 3). IPD-Work=individual participant data meta-analysis in working populations; ARIC=Atherosclerosis Risk in Communities
Study populations in analyses on associations between cognitive stimulation, plasma proteins, and dementia
| Analysis and cohorts | Baseline | Total No | Mean (SD) follow-up (years) | No with dementia | Method of dementia ascertainment | Protein assessment |
|---|---|---|---|---|---|---|
|
| ||||||
| GAZEL | 1997 | 11 362 | 13.7 (1.4) | 14 | Self-reports, deaths | – |
| WOLF | 1992-95 | 10 368 | 14.1 (2.3) | 25 | Hospital admissions, deaths | – |
| HeSSup | 1998 | 15 534 | 14.8 (1.3) | 50 | Hospital admissions, prescriptions, deaths | – |
| HHS | 2000-02 | 6544 | 14.4 (1.8) | 43 | Hospital admissions, prescriptions, deaths | – |
| Whitehall II | 1991-93 | 7475 | 22.1 (3.4) | 183 | Hospital admissions, deaths | – |
| FPS | 2000-02 | 47 448 | 15.5 (1.6) | 313 | Hospital admissions, prescriptions, deaths | – |
| Still Working | 1986 | 9165 | 30.1 (2.2) | 515 | Hospital admissions, prescriptions, deaths | – |
| Pooled total | 107 896 | 16.7 (4.9) | 1143 | |||
|
| ||||||
| Whitehall II (random sample): | ||||||
| Cognitive stimulation | 1991-93 | 2261 | – | |||
| Proteins | 1997-99 | 2261 | 20.4 (3.2) | 109 | – | Somascan, version 4 |
|
| ||||||
| Whitehall II (random sample) | 1997-99 | 2261 | 20.4 (3.2) | 109 | Hospital admissions, deaths | Somascan, version 4 |
| ARIC | 1993-95 | 11 395 | 17.7 (6.1) | 1942 | Clinical examination, Hospital admissions, deaths | Somascan, version 4 |
| Total | 13 656 | 18.1 | 2051 | |||
WOLF=Works, Lipids, and Fibrinogen Stockholm and Norrland studies; HeSSup=Health and Social Support study; FPS=Finnish Public Sector study; ARIC=Atherosclerosis Risk in Communities study.
Characteristics of participants from pooled sample
| Characteristic | No (%) |
|---|---|
| Sex: | |
| Men | 45 080 (41.8) |
| Women | 62 816 (58.2) |
| Mean (SD) age (years) | 44.6 (9.5) |
| Age group (years): | |
| <60 | 105 065 (97.4) |
| ≥60 | 2831 (2.6) |
| Cognitive stimulation at work: | |
| Low | 29 243 (27.1) |
| Medium | 50 724 (47.0) |
| High | 27 929 (25.9) |
| Education: | |
| Low | 26 036 (25.1) |
| Intermediate | 40 723 (39.2) |
| High | 37 171 (35.8) |
| Current smoking: | |
| No | 81 821 (79.1) |
| Yes | 21 580 (20.9) |
| Heavy alcohol intake: | |
| No | 95 043 (89.7) |
| Yes | 10 950 (10.3) |
| Physical inactivity: | |
| No | 82 030 (77.8) |
| Yes | 23 358 (22.2) |
| Obesity (BMI ≥30): | |
| No | 86 611 (89.2) |
| Yes | 10 507 (10.8) |
| Hypertension: | |
| No | 91 858 (86.9) |
| Yes | 13 878 (13.1) |
| Prevalent diabetes: | |
| No | 105 199 (97.5) |
| Yes | 2680 (2.5) |
| Job strain: | |
| No | 90 766 (84.1) |
| Yes | 17 130 (15.9) |
| Prevalent or incident diabetes: | |
| No | 99 970 (92.8) |
| Yes | 7909 (7.3) |
| Prevalent or incident coronary heart disease: | |
| No | 105 540 (97.8) |
| Yes | 2356 (2.2) |
| Prevalent or incident stroke: | |
| No | 105 523 (97.8) |
| Yes | 2373 (2.2) |
Supplementary eTables 1-7 present the characteristics of participants by cohort.
BMI=body mass index.
Fig 2Crude cumulative hazard of dementia by age and level of cognitive stimulation at work
Fig 3Association of cognitive stimulation at work with incident dementia in total sample, subgroups, by study follow-up and dementia type, and in relation to adjustments (analysis 1). *Follow-up started 10 years after baseline and the analysis included only those participants without a diagnosis of dementia by that time. †Adjusted for age, sex, cohort, and education. ‡Adjusted for age, sex, cohort, and smoking, alcohol consumption, physical inactivity, job strain, obesity, hypertension, and prevalent diabetes at baseline. §Adjusted for age, sex, and cohort, and diabetes, coronary heart disease, and stroke (prevalent at baseline and incident between baseline and dementia diagnosis). ¶Adjusted for age, sex, education, risk factors in adulthood, and cardiometabolic diseases
Proteins associated with cognitive stimulation in 2261 participants with plasma proteins available in Whitehall subcohort after controlling for multiple testing (analysis 2)
| Protein | High | Medium | |||
|---|---|---|---|---|---|
| β (SE)* | P value | β (SE)* | P value | ||
| Pulmonary surfactant associated protein D (SP-D) | −0.32 (0.06) | <0.001 | -0.17 (0.06) | 0.002 | |
| Slit homologue 2 protein (SLIT2) | −0.30 (0.06) | <0.001 | −0.17 (0.06) | 0.002 | |
| Hexokinase 2 (HXK2) | −0.28 (0.06) | <0.001 | −0.13 (0.06) | 0.019 | |
| Carbohydrate sulfotransferase 12 (CHSTC) | −0.28 (0.06) | <0.001 | −0.08 (0.06) | 0.18 | |
| Peptidyl-glycine α-amidating monooxygenase (AMD) | −0.28 (0.06) | <0.001 | −0.12 (0.06) | 0.03 | |
| Neutrophil cytosol factor 1 (NCF-1) | −0.27 (0.06) | <0.001 | −0.06 (0.06) | 0.28 | |
Per 1 standard deviation higher protein level. Only statistically significant associations after adjustment for age, sex, ethnicity, and Bonferroni correction for multiple testing (P<1.0×10−5) are shown for high versus low cognitive stimulation.
Association of six plasma proteins with incident dementia in two cohort studies (analysis 3)
| Protein and cohort | Total No | No with dementia | Adjusted hazard ratio (95% CI) for dementia* | Directionally consistent and significant† | |
|---|---|---|---|---|---|
| SLIT2: | |||||
| Whitehall | 2261 | 109 | 1.19 (0.97 to 1.45) | ||
| ARIC | 11 395 | 1942 | 1.12 (1.00 to 1.26) | Yes | |
| Both | 13 656 | 2051 | 1.14 (1.03 to 1.25) | ||
| CHSTC: | |||||
| Whitehall | 2261 | 109 | 1.08 (0.90 to 1.31) | ||
| ARIC | 11 395 | 1942 | 1.22 (1.05 to 1.41) | Yes | |
| Both | 13 656 | 2051 | 1.17 (1.04 to 1.31) | ||
| AMD: | |||||
| Whitehall | 2261 | 109 | 1.11 (0.92 to 1.34) | ||
| ARIC | 11 395 | 1942 | 1.07 (0.99 to 1.16) | Yes | |
| Both | 13 656 | 2051 | 1.08 (1.00 to 1.16) | ||
| HXK2: | |||||
| Whitehall | 2261 | 109 | 1.09 (0.91 to 1.31) | ||
| ARIC | 11 395 | 1943 | 1.03 (0.92 to 1.15) | No | |
| Both | 13 656 | 2051 | 1.05 (0.95 to 1.15) | ||
| SP-D: | |||||
| Whitehall | 2261 | 109 | 1.16 (0.95 to 1.40) | ||
| ARIC | 11 395 | 1943 | 0.98 (0.93 to 1.04) | No | |
| Both | 13 656 | 2051 | 0.99 (0.94 to 1.05) | ||
| NCF-1: | |||||
| Whitehall | 2261 | 109 | 0.94 (0.78 to 1.13) | ||
| ARIC | 11 395 | 1943 | 1.25 (1.12 to 1.41) | No | |
| Both | 13 656 | 1944 | 1.16 (1.05 to 1.28) |
AMD=peptidyl-glycine α-amidating monooxygenase; ARIC=Atherosclerosis Risk in Communities; CHSTC=carbohydrate sulphotransferase 12; HXK2=hexokinase 2; NCF-1=neutrophil cytosol factor 1; SLIT2=slit homologue 2 protein; SP-D=pulmonary surfactant associated protein D.
Adjusted for age, sex, and ethnicity.
Hazard ratio >1 in both cohort studies and P<0.05 in pooled analysis.
Fig 4Association of cognitive stimulation over the life course with incident dementia (post hoc analysis)